新型抗凝剂利伐沙班预防心房颤动患者脑栓塞的研究进展

心房颤动是脑卒中的重要危险因素,药物抗凝治疗是心房颤动一线治疗的首选。传统抗凝剂(如华法林)因出血、频繁监测等原因导致临床应用受限。利伐沙班是一种口服的小分子直接Ⅹa因子抑制剂,作为临床发展的新药,其具有明确的药代动力学及药效学,有望成为传统抗凝剂的替代药物。

Research progress of the new anticoagulant drug rivaroxaban in the prevention of cerebral embolism in patients with atrial fibrillation

Atrial fibrillation is an important risk factor for stroke,and anticoagulant treatment is the first-line therapy of atrial fibrillation.Traditional anticoagulants such as warfarin have some limitations such as bleeding and need of frequent monitoring,which make clinical administration difficulty.Rivaroxaban,now undergoing clinical development,is a small molecule,orally active factor Xa direct inhibitor with predictable pharmacokinetics and pharmacodynamics.It is hoped that rivaroxaban will be a promising alternative to the traditional anticoagulants.